Pathogenic variants in CHEK2, ATM, and PALB2 are thought to confer a breast cancer risk that is above the 20% lifetime threshold for which breast magnetic resonance imaging is considered.24,27 Thus identifying pathogenic variants in any of these three genes in particular can have clear implications for clinical management. This evidence concerns the gene CHEK2 and breast cancer.